PetMed Express reports 21% revenue decline, $57.3M net loss in FY2026

PetMed Express posted fiscal 2026 results with net sales of $179.0 million, down 21.1% year-over-year, and a net loss of $57.3 million including a $26.7 million goodwill impairment charge. The company faces revenue headwinds from declining prescription medication sales but reports sequential quarterly improvement and claims operational cost reductions as foundation for future growth.